COVID-19 (SARS-CoV-2 Infection)

Table of Contents

1. Overview
2. Epidemiology
3. Pathophysiology
4. Etiology and Risk Factors
5. Clinical Presentation
6. Diagnosis
7. Treatment
8. Complications
9. Prognosis
10. Prevention
11. Recent Research and Advances
12. References

1. Overview

COVID-19 (Coronavirus Disease 2019) is an infectious disease caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), a betacoronavirus first identified in Wuhan, Hubei Province, China, in December 2019. SARS-CoV-2 belongs to the order Nidovirales, family Coronaviridae, genus Betacoronavirus, subgenus Sarbecovirus — sharing approximately 79% genome sequence identity with SARS-CoV-1 (2003 outbreak) and 50% with MERS-CoV.

The WHO declared COVID-19 a Public Health Emergency of International Concern (PHEIC) on January 30, 2020, and a pandemic on March 11, 2020. The pandemic has caused over 7 million confirmed deaths globally (likely substantially undercounted) and has profoundly transformed global healthcare, economics, and geopolitics. The WHO ended the COVID-19 PHEIC designation on May 5, 2023, but COVID-19 continues to circulate as an endemic respiratory virus with ongoing evolution of SARS-CoV-2 variants.

COVID-19 manifests across a broad clinical spectrum: from asymptomatic infection (~30–40% of cases) to mild upper respiratory illness, pneumonia, severe ARDS, multi-organ failure, and death. Long COVID (Post-Acute Sequelae of SARS-CoV-2 infection, PASC) — persistent symptoms lasting >12 weeks — affects approximately 10–30% of those infected and represents a major ongoing public health burden.

2. Epidemiology

Global burden (as of early 2024):

• Confirmed cases: >700 million (WHO); estimated true infections likely 2–4 billion.
• Confirmed deaths: >7 million; excess mortality analyses suggest 15–20 million total attributable deaths globally during the pandemic period.
• Vaccination: Over 13.5 billion vaccine doses administered globally.

Variant evolution: SARS-CoV-2 has evolved through successive waves driven by emerging variants: Alpha (B.1.1.7, UK), Beta (B.1.351, South Africa), Gamma (P.1, Brazil), Delta (B.1.617.2, India) — associated with increased transmissibility and (Delta) severity — and the Omicron lineage (B.1.1.529, late 2021 onward). Omicron subvariants (BA.1, BA.2, BA.4/5, BQ.1, XBB.1.5, EG.5 "Eris," JN.1, KP.2, KP.1.1, LB.1) have dominated globally since late 2021, characterized by markedly increased ACE2 binding affinity, immune evasion, and reduced (though not absent) severity compared with Delta in vaccinated/previously infected populations.

Transmission: Primary route is inhalation of respiratory aerosols and droplets containing infectious virions. Airborne transmission predominates in poorly ventilated indoor environments. Close contact droplet transmission also contributes. Fomite transmission is possible but not a major route. Basic reproduction number (R₀): Original Wuhan strain ~2.5; Delta ~5–6; Omicron ~8–15 (approaching measles-level transmissibility).

Incubation period: 2–14 days (median 4–7 days for original strain; 2–4 days for Omicron).

Infectious period: Typically begins 1–2 days before symptom onset; peak infectivity around symptom onset; most transmission occurs within first 5 days of symptoms. Viral shedding (antigen test positivity) may persist 7–10 days.

Risk disparities: Severe illness and death disproportionately affect older adults, racial/ethnic minority communities (driven by structural inequities), low-income populations, and those with underlying comorbidities. SARS-CoV-2 has revealed and amplified pre-existing health inequities globally.

3. Pathophysiology

Viral Entry and Replication

SARS-CoV-2 entry is mediated by the Spike (S) protein, which binds with high affinity to ACE2 (angiotensin-converting enzyme 2) — expressed on type II pneumocytes, vascular endothelium, intestinal enterocytes, myocardium, kidney, brain, and nasal epithelium. Following ACE2 binding, the S protein is cleaved by host cell serine protease TMPRSS2 (or endosomal cathepsin B/L), enabling fusion of viral and cellular membranes and genomic RNA release into the cytoplasm.

Once inside, the positive-sense single-stranded RNA (~30 kb) is directly translated by host ribosomes into the viral replicase complex (pp1a/pp1ab), which generates a negative-sense template for synthesis of genomic and subgenomic mRNAs encoding structural proteins (S, E, M, N) and accessory proteins. Assembly and budding occur at the ER-Golgi intermediate compartment (ERGIC).

Innate and Adaptive Immune Response

SARS-CoV-2 employs multiple mechanisms to evade early innate immune detection: ORF3b and ORF6 antagonize interferon signaling; NSP1 blocks host mRNA translation; NSP3/4/6 form double-membrane vesicles (DMVs) that shield viral RNA from cytosolic PRR sensing. This delayed IFN response allows viral amplification before effective innate immunity mounts — a key feature distinguishing SARS-CoV-2 from less pathogenic coronaviruses.

In most patients, adaptive immune responses (neutralizing antibodies, CD4+ and CD8+ T-cells) control infection within 1–2 weeks. In some patients — particularly elderly or immunocompromised individuals — the immune response is dysregulated, generating a hyperinflammatory cytokine storm (IL-6, IL-1β, TNF-α, IFN-γ, CXCL10/IP-10) that drives immune-mediated organ injury disproportionate to direct viral damage.

COVID-19 Pulmonary Disease

Direct viral cytopathic effects on type II pneumocytes impair surfactant production and alveolar repair. Endothelial injury and complement activation drive alveolar-capillary barrier disruption, neutrophil influx, macrophage activation, and diffuse alveolar damage (DAD) — the histopathologic correlate of ARDS. The pathological hallmarks of severe COVID-19 lung disease include hyaline membrane formation, organizing pneumonia, fibrin microthrombi in pulmonary capillaries (COVID coagulopathy/immunothrombosis), and a distinctive pattern of alveolar macrophage accumulation.

COVID-19 Coagulopathy

SARS-CoV-2 infection causes a prothrombotic state through: endothelial infection and activation, platelet hyperactivation (NETosis-mediated), elevated von Willebrand factor and factor VIII, elevated fibrinogen, and neutrophil extracellular trap (NET) formation — driving both macro- and microvascular thrombotic complications including DVT/PE, arterial thrombosis, and pulmonary microthrombosis even in the absence of DIC.

Long COVID Pathophysiology

Proposed mechanisms (not mutually exclusive): viral persistence in tissue reservoirs (gut, lymph nodes) with ongoing antigen stimulation; reactivation of Epstein-Barr virus and other latent herpesviruses; autoantibody generation (anti-ACE2, anti-cytokine, anti-G-protein-coupled receptor antibodies); microbiome dysbiosis; microglial activation and neuroinflammation (cognitive/neuropsychiatric PASC); and persistent platelet activation and microclot formation.

4. Etiology and Risk Factors

Risk Factors for Severe COVID-19

Age is the dominant risk factor: infection fatality rate increases exponentially with age (IFR approximately 0.001% for children <10, 0.05% for ages 20–49, 0.6% for 50–69, 3.5% for 70+). Each decade of age approximately doubles the risk of death from COVID-19.

• Comorbidities: Obesity (BMI >30, especially BMI >40), type 2 diabetes mellitus, cardiovascular disease (CAD, heart failure, hypertension), chronic lung disease (COPD, asthma, ILD), chronic kidney disease, chronic liver disease (especially cirrhosis), cerebrovascular disease, sickle cell disease.
• Immunocompromising conditions: Active hematologic or solid tumor malignancies, organ transplant recipients, those on high-dose corticosteroids or other immunosuppressants, HIV with CD4 <200, primary immunodeficiency syndromes, B-cell depleting therapy (rituximab).
• Pregnancy: Increased risk of ICU admission, preterm birth, and maternal mortality; particularly high risk in third trimester.
• Smoking: Current smoking associated with increased severity; vaping associated with lung injury.
• Male sex: Males at approximately 1.5–2× higher risk of severe disease and death vs. females at any given age, potentially related to sex differences in ACE2 expression and immune response.
• Genetics: Loss-of-function variants in TLR7 (X-linked), TLR3, type I IFN pathway genes (IRF7, IRF3, IFNAR); neutralizing anti-type I IFN autoantibodies (~4% of critical disease cases, particularly older men); ABO blood group (type A higher risk).

5. Clinical Presentation

WHO Severity Classification

• Asymptomatic infection: Positive test, no symptoms.
• Mild illness: Symptomatic without pneumonia or hypoxia.
• Moderate illness: Pneumonia (clinical or radiographic) without hypoxia (SpO₂ ≥94% on room air).
• Severe illness: Pneumonia with SpO₂ <94% on room air, respiratory rate >30/min, PaO₂/FiO₂ <300, or lung infiltrates >50%.
• Critical illness: Respiratory failure (ARDS), septic shock, and/or multiorgan dysfunction.

Symptom Profile

Classic COVID-19 symptoms (original/Delta): Fever (77–98%), dry cough (59–82%), fatigue (29–70%), dyspnea (18–59%), myalgia/arthralgia (11–44%), headache (8–40%), sore throat (11–13%), anosmia/ageusia (loss of smell/taste, pathognomonic, now less common with Omicron), nasal congestion/rhinorrhea, gastrointestinal symptoms (diarrhea, nausea, vomiting in 15–20%), conjunctivitis.

Omicron-era symptoms: Predominantly upper respiratory (rhinorrhea, sore throat, sneezing, hoarseness), with lower rates of anosmia/ageusia compared with prior variants. More flu-like presentation. Dyspnea and hypoxia less frequent overall, but still prevalent in high-risk individuals.

Clinical course: Most non-severe illness resolves within 10–14 days. Severe disease: hypoxia typically develops 5–8 days after symptom onset; ARDS at 8–12 days. Cytokine storm peak approximately day 8–12.

Multisystem inflammatory syndrome in children (MIS-C): Rare (1:3,000–10,000 SARS-CoV-2 infections in children); occurs 2–6 weeks post-infection; fever, mucocutaneous changes (Kawasaki-like), GI symptoms, cardiac involvement (myocarditis, coronary artery dilation), shock; markedly elevated inflammatory markers; treated with IVIG ± aspirin ± corticosteroids.

Multisystem inflammatory syndrome in adults (MIS-A): Less common; similar features with cardiac and shock predominance.

6. Diagnosis

Virologic Testing

• Nucleic acid amplification test (NAAT/PCR): Gold standard. Nasopharyngeal or anterior nasal swab; oropharyngeal swab alone is less sensitive. Sensitivity 85–97% with NP swab; near-100% specificity. Highly sensitive even at low viral loads; may remain positive for weeks in immunocompromised hosts (not necessarily indicating infectiousness).
• Antigen tests (rapid tests): Detects SARS-CoV-2 nucleocapsid protein. Less sensitive than PCR (sensitivity 50–85%, highest when symptomatic and high viral load), but highly specific (>99%), inexpensive, rapid (15 minutes), and suitable for point-of-care and home use. Negative result does not exclude COVID-19 if symptoms present; serial testing (48 hours apart) improves sensitivity. FDA-authorized tests available; updated formulations target newer variants.
• Specimen types: NP swab (highest sensitivity), anterior nasal swab (acceptable), oropharyngeal swab, saliva, BAL/sputum (for lower respiratory disease).

Serologic Testing

IgM/IgG/IgA antibody assays. Not for acute diagnosis (seroconversion occurs 7–14 days post-infection). Useful for: epidemiologic surveillance, documenting prior infection, assessing vaccine response (anti-spike IgG) in immunocompromised patients. Anti-nucleocapsid (anti-N) antibodies indicate natural infection; anti-spike (anti-S) antibodies may reflect natural infection or vaccination.

Clinical Assessment Tools

• Chest CT: Typical COVID-19 findings — bilateral, peripheral, lower lobe–predominant ground-glass opacities (GGOs) ± consolidation, "crazy paving" pattern. CT-severity score correlates with outcomes. CO-RADS classification system for reporting. CT not recommended for routine diagnosis; reserved for undifferentiated severe respiratory illness or ambiguous presentation.
• Chest X-ray: Bilateral interstitial infiltrates, airspace opacification; often lags clinical severity.
• Point-of-care ultrasound (POCUS): B-lines, sub-pleural consolidations, pleural irregularities — useful bedside tool in resource-limited settings and for monitoring progression.
• Laboratory: Complete blood count (lymphopenia — a sentinel feature, neutrophilia in severe disease), CRP, LDH, D-dimer, ferritin (hyperferritinemia correlated with cytokine storm), troponin (myocarditis/cardiac injury), BNP/NT-proBNP, liver function tests, creatinine, ABG.
• Prognostic biomarkers: Elevated IL-6 (>50 pg/mL), ferritin (>500 ng/mL), D-dimer (>1 mg/L), LDH (>245 U/L), CRP (>100 mg/L), lymphopenia, and neutrophil-to-lymphocyte ratio (NLR >3.13) are independently associated with severe disease and death.

7. Treatment

Outpatient Antiviral Therapy (High-Risk Patients)

• Nirmatrelvir/ritonavir (Paxlovid): Oral protease inhibitor combination; 300/100 mg twice daily × 5 days. Must initiate within 5 days of symptom onset. Reduces hospitalization/death by ~89% (EPIC-HR trial) in unvaccinated high-risk adults; ~51% reduction in EPIC-SR in standard-risk vaccinated adults. Ritonavir component causes significant drug-drug interactions (CYP3A4 inhibition); requires careful medication review. Rebound (COVID rebound) occurs in 2–5% — generally mild. Dose adjustment required for eGFR <30; contraindicated for eGFR <30 ml/min.
• Remdesivir (outpatient, 3-day IV course): Nucleotide analog inhibiting viral RNA polymerase; 200 mg IV day 1, then 100 mg IV days 2–3. Reduces hospitalization by 87% (PINETREE trial) in high-risk non-hospitalized patients when initiated within 7 days of symptom onset.
• Molnupiravir (Lagevrio): Oral nucleoside analog; 800 mg twice daily × 5 days; reduced hospitalization by 30% (MOVe-OUT trial) — lower efficacy than Paxlovid; reserved for when Paxlovid and remdesivir are unavailable or contraindicated. Potential mutagenicity: avoid in pregnancy and in patients who may transmit to pregnant contacts.

Hospitalized Patients — Non-Severe

• Remdesivir 200 mg IV day 1, then 100 mg IV days 2–5 for patients requiring supplemental oxygen but not high-flow or mechanical ventilation.
• Dexamethasone 6 mg IV/PO daily × 10 days — specifically for patients requiring oxygen supplementation. Avoid dexamethasone in non-hypoxic patients (RECOVERY trial showed possible harm in non-oxygen-requiring patients).

Severe/Critical COVID-19

• Dexamethasone 6 mg daily × 10 days: Cornerstone of severe COVID-19 treatment; 36% reduction in 28-day mortality for ventilated patients (RECOVERY trial). Higher doses (12 mg) may benefit most critically ill patients.
• IL-6 receptor antagonists: Tocilizumab 8 mg/kg IV (max 800 mg) × 1 dose OR sarilumab 400 mg IV × 1 dose; added to dexamethasone for rapidly escalating oxygen requirements, ICU admission, or markedly elevated CRP (>75 mg/L). REMAP-CAP and RECOVERY trials demonstrate mortality benefit.
• Baricitinib (Olumiant): JAK1/2 inhibitor; 4 mg PO daily × 14 days; added to dexamethasone for severe disease; non-inferior to tocilizumab; can be combined with remdesivir. ACTT-2 and COV-BARRIER trials support use.
• Anticoagulation: Prophylactic anticoagulation with LMWH (enoxaparin) for all hospitalized COVID-19 patients without contraindication. Therapeutic anticoagulation for confirmed VTE. For non-ICU patients with D-dimer >2× upper limit and without high bleeding risk: therapeutic anticoagulation may be beneficial (ACTIV-4a, ATTACC, REMAP-CAP platform trial).
• Mechanical ventilation: Low tidal volume strategy (6 mL/kg IBW), prone positioning for P:F <150 (12–16 hours/day), conservative fluid strategy, neuromuscular blockade for ventilator dyssynchrony, PEEP optimization per ARDSnet table.
• ECMO: Considered for refractory ARDS (VV-ECMO) or cardiogenic shock (VA-ECMO) at experienced centers.

Monoclonal Antibodies

Prior monoclonal antibody products (casirivimab/imdevimab, bamlanivimab, sotrovimab, bebtelovimab) have largely lost activity against circulating Omicron subvariants. As of 2024, no currently authorized mAbs retain broad Omicron activity — underscoring the importance of small-molecule antivirals for high-risk outpatients.

8. Complications

Acute Complications

• ARDS: Most common cause of COVID-19 ICU admission; distinct "L-type" (low elastance) and "H-type" (high elastance) phenotypes described.
• COVID-19 coagulopathy: DVT (25–30% of ICU patients), pulmonary embolism (the most frequent VTE), arterial thrombosis (stroke, MI, mesenteric ischemia), microvascular thrombosis in lungs/kidneys/heart.
• Acute kidney injury: 30–50% of ICU patients; mechanisms include direct tubular injury, cytokine-mediated damage, thrombotic microangiopathy, and sepsis-associated AKI.
• Myocarditis and pericarditis: Rare but significant; direct viral myocardial infection and immune-mediated mechanisms; can cause arrhythmias, cardiogenic shock, and sudden death.
• Secondary bacterial and fungal infections: Ventilator-associated pneumonia, COVID-19-associated pulmonary aspergillosis (CAPA, particularly in immunocompromised and steroid-treated ICU patients), Candida and mucormycosis ("black fungus" epidemic during Delta wave in India).
• Cytokine release syndrome (CRS): Macrophage activation syndrome–like hyperinflammatory state.
• Neurologic complications: Encephalopathy (most common, 20–40% of ICU), ischemic and hemorrhagic stroke, Guillain-Barré syndrome, transverse myelitis.

Long COVID (PASC)

Affecting an estimated 10–30% of those infected (higher rates with initial severe illness, lower with vaccination and Omicron). Defined as symptoms persisting >12 weeks post-acute infection not explained by alternative diagnosis. Common manifestations: fatigue (>50%), post-exertional malaise (PEM — hallmark), cognitive impairment ("brain fog"), dyspnea, palpitations, headache, sleep disturbance, musculoskeletal pain, depression/anxiety, anosmia/ageusia. Autonomic dysfunction including POTS (postural orthostatic tachycardia syndrome) is recognized as a major Long COVID phenotype.

9. Prognosis

Overall COVID-19 prognosis has substantially improved since 2020 due to vaccination, effective antivirals, improved critical care protocols, and reduced virulence of dominant variants. Key determinants:

• Infection fatality rate (IFR): Meta-analyses estimate IFR of 0.05–0.1% in pre-vaccine era overall; <0.1% in vaccinated populations for Omicron variants.
• Hospitalized severe COVID-19 mortality: Reduced from approximately 30–40% in early pandemic to <10–15% in fully vaccinated patients receiving optimal care.
• ICU mortality: Remains approximately 25–40% for mechanically ventilated patients.
• Predictors of poor outcome: Age >65, immunocompromise, multiple comorbidities, high D-dimer, lymphopenia, elevated IL-6 and ferritin, bilateral extensive infiltrates.
• Vaccination: Dramatically reduces risk of severe disease, hospitalization, and death — estimated 90%+ reduction in mortality in fully boosted individuals across all age groups.
• Long COVID prognosis: Many patients improve over months; a subset experiences prolonged disability. Vaccination reduces Long COVID risk by approximately 50%.

10. Prevention

Vaccination

COVID-19 vaccines represent the most important preventive intervention. Platform types and products:

• mRNA vaccines: Pfizer-BioNTech BNT162b2 (Comirnaty) and Moderna mRNA-1273 (Spikevax) — encode SARS-CoV-2 spike protein in lipid nanoparticle delivery system; repeatedly updated to match dominant variants (bivalent, XBB.1.5, JN.1-based compositions). Highly effective against severe disease in all age groups; recommended for primary series and annual booster updates.
• Protein subunit: Novavax NVX-CoV2373 (Nuvaxovid) — recombinant spike protein + Matrix-M adjuvant; approved for adults as alternative for those preferring non-mRNA vaccine.
• Adenoviral vector: Johnson & Johnson Ad26.COV2.S (Janssen), AstraZeneca ChAdOx1 nCoV-19 (Vaxzevria) — largely superseded due to rare VITT (vaccine-induced immune thrombocytopenia and thrombosis) risk and inferior durability vs. mRNA vaccines.
• Inactivated virus: Sinovac CoronaVac, Sinopharm BBIBP-CorV — widely deployed in Asia, Africa, Latin America; lower and less durable efficacy than mRNA vaccines.

Updated annual COVID-19 vaccine (matching dominant circulating variant) is recommended by the CDC/ACIP for all individuals ≥6 months, with particular emphasis on adults ≥65, immunocompromised patients (who may require additional doses), and healthcare workers.

Non-Pharmacologic Prevention

• Respiratory hygiene: High-filtration masks (N95/KN95/FFP2) provide substantial protection against aerosol transmission; surgical masks are less effective but better than cloth masks.
• Ventilation: HEPA filtration and CO₂ monitoring of indoor air quality; increased outdoor air exchange reduces aerosol concentration.
• Hand hygiene: Frequent handwashing with soap and water ≥20 seconds or alcohol-based hand rub; less critical for COVID-19 vs. influenza but important for general infection control.
• Isolation: Infected individuals should isolate for ≥5 days from symptom onset (or positive test date if asymptomatic); continue masking until resolution of symptoms and negative antigen test.
• Pre-exposure prophylaxis for immunocompromised: Long-acting monoclonal antibody tixagevimab/cilgavimab (Evusheld) has lost neutralizing activity against Omicron; no currently authorized pre-exposure prophylaxis mAb available as of 2024. Passive immunization research ongoing.

11. Recent Research and Advances

• Long COVID mechanistic research: The NIH RECOVER initiative (Research on COVID to Enhance Recovery) has enrolled >17,000 participants. Key 2023–2024 findings: viral RNA and protein persistence in GI and other tissues months after acute infection in PASC patients (Proal et al.); EBV reactivation in Long COVID patients; autoantibody signatures (anti-G-protein-coupled receptor mAbs); microclot formation and fibrin-amyloid microaggregates in blood (Pretorius et al.).
• Long COVID treatment trials: RECOVER-VITAL trial testing Paxlovid for Long COVID (hypothesis: persistent viral reservoir); RECOVER-NEURO trials for cognitive PASC; anticoagulation trials for microclot hypothesis; low-dose naltrexone; BC007 for autoantibody removal.
• Updated vaccines: 2024–2025 vaccine compositions target JN.1/KP.2 lineage; mRNA technology allows rapid update. Mucosal vaccines (intranasal) in clinical trials to improve upper respiratory tract immunity and reduce transmission.
• Next-generation antivirals: Ensitrelvir (Xocova, approved in Japan), S-217622 in Phase 3; lumicitabine and other broad-spectrum coronavirals in development.
• SARS-CoV-2 origins: Ongoing scientific investigation; current evidence favors zoonotic spillover at Wuhan Huanan Seafood Market; exact proximal animal host not definitively identified.
• Pandemic preparedness: Coalition for Epidemic Preparedness Innovations (CEPI) 100-days Mission to develop vaccines within 100 days of novel pathogen identification; WHO pandemic treaty negotiations ongoing.
• COVID-19 and cardiovascular disease: Large RECOVERY data and observational cohorts confirm excess risk of myocardial infarction, stroke, heart failure, and arrhythmia up to 1 year post-acute infection even in mild cases (Al-Aly et al., Nature 2022).

12. References

1. WHO. COVID-19 Weekly Epidemiological Update. World Health Organization. https://www.who.int/publications/m/item/covid-19-weekly-epidemiological-update
2. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733. https://doi.org/10.1056/NEJMoa2001017
3. RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384:693–704. https://doi.org/10.1056/NEJMoa2021436
4. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19 (EPIC-HR). N Engl J Med. 2022;386:1397–1408. https://doi.org/10.1056/NEJMoa2118542
5. REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021;385:777–789. https://doi.org/10.1056/NEJMoa2103417
6. REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384:1491–1502. https://doi.org/10.1056/NEJMoa2100433
7. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259–264. https://doi.org/10.1038/s41586-021-03553-9
8. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263. https://doi.org/10.1126/science.abb2507
9. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine (Pfizer-BioNTech). N Engl J Med. 2020;383:2603–2615. https://doi.org/10.1056/NEJMoa2034577
10. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine (Moderna). N Engl J Med. 2021;384:403–416. https://doi.org/10.1056/NEJMoa2035389
11. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133–146. https://doi.org/10.1038/s41579-022-00846-2
12. Proal AD, VanElzakker MB, Aleman S, et al. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19. Nat Immunol. 2023;24:1137–1150. https://doi.org/10.1038/s41590-023-01601-2
13. Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 (IVY Network). MMWR Morb Mortal Wkly Rep. 2020;69:993–998. https://doi.org/10.15585/mmwr.mm6930e1
14. Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States. BMJ. 2022;376:e069761. https://doi.org/10.1136/bmj-2021-069761
15. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19. N Engl J Med. 2020;383:1813–1826. https://doi.org/10.1056/NEJMoa2007764
16. Coronavirus Disease (COVID-19) treatment guidelines. NIH COVID-19 Treatment Guidelines Panel. https://www.covid19treatmentguidelines.nih.gov

Back to Table of Contents